Dashyant Dhanak - Sep 15, 2023 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
EVP & Chief Scientific Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Stock symbol
DCPH
Transactions as of
Sep 15, 2023
Transactions value $
$0
Form type
4
Date filed
9/19/2023, 05:05 PM
Previous filing
Sep 5, 2023
Next filing
Feb 20, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Award $0 +65.9K $0.00 65.9K Sep 15, 2023 Direct F1
transaction DCPH Common Stock Award $0 +75K +113.81% $0.00 141K Sep 15, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $0 +65.9K $0.00 65.9K Sep 15, 2023 Common Stock 65.9K $13.42 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was awarded 65,900 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in three equal annual installments on each of September 15, 2024, September 15, 2025 and September 15, 2026.
F2 The reporting person was awarded 75,000 RSUs. These RSUs will vest in two equal annual installments on each of September 15, 2024 and September 15, 2025.
F3 This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the shares underlying the option shall vest on September 15, 2024, with the remainder vesting in 36 equal monthly installments thereafter.